ZOONO GROUP LIMITED (ZNO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ZNO

ZNO - ZOONO GROUP LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Materials
Debt/EBITDA: N/A
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.03

04 Apr
2025

0.002

OPEN

$0.03

7.14%

HIGH

$0.03

1,263,737

LOW

$0.03

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

Last ex-div: 04/09 - ex-div 3c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved

EPS Basic

201920202021202220232024-50510
  • Negative
  • Growth
  • Slowing

DPS All

2019202020212022202320240123
  • Negative
  • Growth
  • Slowing

Sales/Revenue

201920202021202220232024010203040
  • Negative
  • Growth
  • Slowing

Book Value Per Share

2019202020212022202320240246810
  • Negative
  • Growth
  • Slowing

Net Operating Cash Flow

201920202021202220232024-50510
  • Negative
  • Growth
  • Slowing

Net Profit Margin

201920202021202220232024-900-700-500-300-100100
  • Negative
  • Growth
  • Slowing

Return on Capital Employed

201920202021202220232024-200-1000100200
  • Negative
  • Growth
  • Slowing

Return on Invested Capital

201920202021202220232024-1000100200
  • Negative
  • Growth
  • Slowing

Return on Assets

201920202021202220232024-100-50050100
  • Negative
  • Growth
  • Slowing

Return on Equity

201920202021202220232024-200-1000100200
  • Negative
  • Growth
  • Slowing

Return on Total Capital

201920202021202220232024-1000100200
  • Negative
  • Growth
  • Slowing

Free Cash Flow ex dividends

201920202021202220232024-50510
  • Negative
  • Growth
  • Slowing

Short-Term Debt

20192020202120222023202400.10.20.30.4
  • Negative
  • Growth
  • Slowing

Long Term Debt

20192020202120222023202400.511.52
  • Negative
  • Growth
  • Slowing

Total Debt

20192020202120222023202400.511.52
  • Negative
  • Growth
  • Slowing

Goodwill - Gross

2019202020212022202320240246
  • Negative
  • Growth
  • Slowing

Cash & Equivalents - Generic

2019202020212022202320240246810
  • Negative
  • Growth
  • Slowing

Price To Book Value

2019202020212022202320240102030
  • Negative
  • Growth
  • Slowing

Capex

20192020202120222023202400.20.40.6
  • Negative
  • Growth
  • Slowing

Capex % of Sales

2019202020212022202320240123
  • Negative
  • Growth
  • Slowing

Cost of Goods Sold

201920202021202220232024051015
  • Negative
  • Growth
  • Slowing

Selling, General & Admin. Exp & Other

20192020202120222023202402468
  • Negative
  • Growth
  • Slowing

Research & Development

Investments - Total

20192020202120222023202400.250.50.751
  • Negative
  • Growth
  • Slowing
  • Negative
  • Growth
  • Slowing
    • EXPERT VIEWS
    Display All Commentary

    Sentiment Indicator

    0.0

    No. Of Recommendations

    0
    Access Stockbroker Research History >
    EXTRA COVERAGE
    Display All Commentary

    No. Of Recommendations

    0

    Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

    Access Extra Coverage Research History >

    ZNO STOCK CHART

    FNArena News on ZNO

    1
    Hand Sanitisers: Clean Up Or Clean Out?

    Apr 22 2020 - Weekly Reports

    Latest Pharmaceuticals & Biotech/Lifesciences News

    1
    Behring Margin Outlook Still Main Game For CSL

    Feb 13 2025 - Australia
    2
    Dr Boreham’s Crucible: Arovella Therapeutics

    Aug 29 2024 - Small Caps
    3
    ResMed’s Margin Upside Excites

    Aug 07 2024 - Australia
    4
    Dr Boreham’s Crucible: Aroa Biosurgery

    Jul 29 2024 - Small Caps
    5
    CSL Shares Breaking Free

    Jul 23 2024 - Technicals
    6
    Dr Boreham’s Crucible: SDI

    Jul 19 2024 - Small Caps
    7
    ‘Defensive’ Pharmaceutical Wholesalers In Focus

    Jul 18 2024 - Australia
    8
    Twists And Turns Of Telix And Australian Biotech

    Jul 10 2024 - Small Caps
    9
    Dr Boreham’s Crucible: Radiopharm Theranostics

    Jul 03 2024 - Small Caps
    10
    Dr Boreham’s Crucible: Island Therapeutics

    Jun 17 2024 - Small Caps